What was recalled
This page synthesizes the regulatory and biochemical framework around arachidonic acid as a feline obligate-carnivore essential fatty acid. Arachidonic acid (20:4 omega-6) is a four-double-bond polyunsaturated fatty acid synthesized via the omega-6 elongation/desaturation pathway from linoleic acid. The enzymatic sequence is: linoleic acid (LA, 18:2) → gamma-linolenic acid (GLA, 18:3) via delta-6 desaturase → dihomo-gamma-linolenic acid (DGLA, 20:3) via elongase → arachidonic acid (AA, 20:4) via delta-5 desaturase. Delta-6 desaturase is the rate-limiting enzyme in most mammals. Cats are structurally limited at this step; hepatic delta-6 desaturase activity is less than 10% of canine activity in measurement studies, and the practical conversion of dietary linoleic acid to arachidonic acid is insufficient to meet biological requirements in cats. The metabolic limitation reflects the cat's evolutionary obligate carnivore biology — wild felid diets contain pre-formed arachidonic acid from prey tissue, so the elongation/desaturation pathway has been under reduced selective pressure across feline evolution.
Arachidonic acid functions in cats include: substrate for prostaglandin E2, F2alpha, and thromboxane A2 synthesis (regulating inflammation, vascular tone, platelet aggregation, parturition); structural incorporation into cell membrane phospholipids (particularly neural and reproductive tissue membranes); precursor for leukotriene B4 and C4/D4/E4 (immune signaling); precursor for endocannabinoids (anandamide, 2-AG); and substrate for cytochrome P450-derived epoxyeicosatrienoic acids (vascular and renal function). The breadth of biological function means deficiency produces multi-system clinical signs rather than a narrow phenotype. AAFCO Nutrient Profile mandates 200 mg/kg dry matter for feline adult maintenance and growth; the mandate reflects the established obligate-carnivore biology and is not species-shared with the dog AAFCO profile.
Why it was recalled
The structural controversy has three layers. Layer one — vegan cat food category growth: the vegan and vegetarian cat food category has grown despite ACVN, ACVIM, and ISFM consensus warnings about obligate-carnivore inadequacy. Driven by owner ethical preferences regarding animal agriculture and perceived environmental sustainability, vegan cat food brands (Wysong Vegan, Ami Cat, Evolution Diet, Benevo) have established sustained market presence. AAFCO compliance for vegan cat food requires synthetic arachidonic acid supplementation or mycelial fermentation-derived AA from Mortierella alpina (the same organism used to produce DHA-rich algae oil alternatives). Without specific AA supplementation, vegan cat food is structurally inadequate regardless of total omega-6 content from plant sources.
Layer two — label transparency gap: commercial cat food labels rarely disclose arachidonic acid content separately from total omega-6 fatty acids. A pet owner cannot readily distinguish a meat-based cat food with adequate AA from a plant-based cat food without specific AA supplementation by reading the Guaranteed Analysis alone. The ingredient deck reveals whether animal-source ingredients (organ meat, egg, animal fat, fish) provide AA naturally versus whether plant-based formulations include synthetic AA supplementation explicitly. Some vegan cat food brands disclose AA supplementation explicitly; others do not, leaving consumers uncertain about adequacy.
Layer three — long-term feeding outcome ambiguity: peer-reviewed feeding-trial evidence on vegan cat food long-term outcomes is limited; existing studies show mixed results with some cohorts maintaining clinical adequacy and others developing taurine, AA, vitamin A, or amino-acid deficiency signs. ACVN consensus reflects the precautionary principle: in the absence of robust evidence demonstrating long-term safety, an obligate-carnivore species should not be fed a non-carnivore diet without rigorous formulation oversight, periodic veterinary monitoring (taurine, retinol, fatty acid panels), and immediate intervention if clinical signs emerge. The vegan-vegetarian pet food adequacy page covers the broader framework; arachidonic acid is one component of the obligate-carnivore concern set.
Health risks for your pet
Arachidonic acid deficiency in cats produces multi-system clinical signs reflecting the breadth of AA biological function. Dermatologic signs include dry, scaly coat, alopecia, poor wound healing, and increased susceptibility to skin infection — reflecting AA incorporation into skin lipid barrier and the eicosanoid contribution to wound healing. Reproductive signs include poor estrous cycling, conception failure, fetal resorption, and reduced kitten viability — reflecting AA requirement for prostaglandin-mediated reproductive physiology. Immune signs include increased infection susceptibility and dysregulated inflammatory response — reflecting AA contribution to leukotriene-mediated immune signaling. Neurological signs in severe chronic deficiency include behavioral changes and reduced cognitive function — reflecting AA incorporation into neural membrane phospholipids.
The clinical phenotype is rarely classical "AA deficiency" — instead, vegan-cat-food-fed cats may present with non-specific signs that resolve on transition to AA-supplemented or animal-source diets. The structural concern at the population level is subclinical chronic deficiency that affects long-term health without producing acute clinical recognition. Pet owners feeding vegan cat food without explicit AA supplementation disclosure are accepting an uncertain risk profile. The kitten growth and pregnant queen populations are particularly sensitive: developmental and reproductive AA demand exceeds maintenance, and deficiency consequences may be irreversible. The ACVN consensus position emphasizes that pregnant queens and growing kittens should not be fed vegan diets without veterinary oversight and routine fatty acid monitoring.
What to do if you bought affected product
Pet owners can manage feline arachidonic acid adequacy through several practical approaches: (1) animal-source-based cat food provides AA naturally from organ meat, egg, animal fat, fish, and shellfish ingredients; ingredient-deck inspection for these components is the simplest adequacy signal; (2) vegan or vegetarian cat food requires explicit AA supplementation disclosure — synthetic arachidonic acid or mycelial-fermentation-derived AA (Mortierella alpina) should be listed in the ingredient deck or supplementation panel; brands declining to disclose AA supplementation should be treated as inadequate for cats; (3) periodic plasma fatty acid monitoring for cats on vegan diets — annual plasma AA, EPA, DHA, and linoleic acid panel reveals subclinical deficiency before clinical signs emerge; work with veterinarian to interpret results and adjust supplementation; (4) kittens and pregnant queens should not be fed vegan diets without rigorous formulation oversight and routine fatty acid monitoring; the developmental and reproductive demand exceeds maintenance and consequences of deficiency may be irreversible; (5) parallel obligate-carnivore concerns apply alongside AA — taurine (see synthetic taurine pet food), vitamin A retinol versus beta-carotene conversion, vitamin D D3 versus D2 conversion, vitamin B12 cobalamin availability; the framework matters across multiple nutrients, not just AA; (6) ACVN consensus recommends that cats not be fed vegan diets without rigorous formulation oversight; pet owners choosing vegan cat food should engage a board-certified veterinary nutritionist (DACVN) or use brands with documented AAFCO-feeding-trial compliance specifically for the formulation in use.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 awards scoring credit for explicit arachidonic acid supplementation in cat food formulations per our published methodology, with vegan cat food formulations lacking documented AA supplementation receiving substantial scoring penalty for the structural obligate-carnivore inadequacy concern. The rubric does not currently penalize meat-based cat food formulations relying on natural AA from animal ingredients, since AAFCO-feeding-trial-validated formulations using animal-source ingredients are biologically adequate. Pet owners choosing vegan cat food should prioritize brands with explicit AA supplementation, documented AAFCO feeding-trial compliance for the specific formulation in use, and routine plasma fatty acid monitoring as part of ongoing care. The ACVN consensus position remains that cats should not be fed vegan diets without rigorous oversight.